...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Accelerated approval

Great post narmac. I'm expecting the same old again although it must be getting a bit tough for Don to make up his dodges each year.

I feel the only hope in the short term is that if some suitor bites on the mCRPC trial with a CVR type deal or better and I think the probabilityof that is 1% based on my last 10 years.

I still believe their focus is to get something right and of value out of RVX and then turn attention to ZE unless ZE has a blockbuster and that is certainly not evident at this stage.

GLTA

Toinv

Share
New Message
Please login to post a reply